Therapeutic potential of FAPI RLT in oncology: A systematic review.

ABSTRACT: Rationale: This systematic review aims to examine the safety and efficacy of fibroblast activation protein inhibitor (FAPI) radioligand therapy (RLT) for various epithelial neoplasms. Methods: PubMed, Web of Science, and Scopus databases were searched up to Jan 4, 2025, for studies involving FAPI RLT in various cancers. Data extraction focused on exploring safety and efficacy of FAPI RLT. Results: Overall, 27 studies involving a total of 144 patients who received FAPI RLT were included in this systematic review. [¹⁷⁷Lu]Lu-FAPI was employed in 21 studies, with 225 cycles administered to 95 patients at a median dose of 6.8 GBq/cycle. Six non-randomized clinical investigations using [¹⁷⁷Lu]Lu-FAPI reported disease control rates ranging from 18.2% to

SUBMITTER: Ruzzeh S 

PROVIDER: S-EPMC11980674 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature